Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Assessing the evidence for maternal pertussis immunization: A report from the bill and melinda gates foundation symposium on pertussis infant disease burden in low-and lower-middle-income countries
Clinical Infectious Diseases, Volume 63, Year 2016
Notification
URL copied to clipboard!
Description
Implementation of effective interventions has halved maternal and child mortality over the past 2 decades, but less progress has been made in reducing neonatal mortality. Almost 45% of under-5 global mortality now occurs in infants <1 month of age, with approximately 86% of neonatal deaths occurring in low-and lower-middle-income countries (LMICs). As an estimated 23% of neonatal deaths globally are due to infectious causes, maternal immunization (MI) is one intervention that may reduce mortality in the first few months of life, when direct protection often relies on passively transmitted maternal antibodies. Despite all countries including pertussis-containing vaccines in their routine childhood immunization schedules, supported through the Expanded Programme on Immunization, pertussis continues to circulate globally. Although based on limited robust epidemiologic data, current estimates derived from modeling implicate pertussis in 1% of under-5mortality, with infants too young to be vaccinated at highest risk of death. Pertussis MI programs have proven effective in reducing infant pertussis mortality in high-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines in their maternal and infant programs; however, these vaccines are cost-prohibitive for routine use in LMICs. The reach of antenatal care programs to deliver maternal pertussis vaccines, particularly with respect to infants at greatest risk of pertussis, needs to be further evaluated. Recognizing that decisions on the potential impact of pertussis MI in LMICs need, as a first step, robust contemporary mortality data for early infant pertussis, a symposium of global key experts was held. The symposium reviewed current evidence and identified knowledge gaps with respect to the infant pertussis disease burden in LMICs, and discussed proposed strategies to assess the potential impact of pertussis MI. © The Author 2016.
Authors & Co-Authors
Sobanjo-ter Meulen, Ajoke
Unknown Affiliation
Duclos, Philippe J.
Switzerland, Geneva
Organisation Mondiale de la Santé
Mcintyre, Peter B.
Australia, Parramatta
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Australia
Lewis, Kristen D.C.
Unknown Affiliation
Van-Damme, Pierre A.
Belgium, Antwerpen
Universiteit Antwerpen
O'Brien, Katherine L.
United States, Baltimore
Johns Hopkins Bloomberg School of Public Health
Klugman, K. P.
Unknown Affiliation
Statistics
Citations: 30
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1093/cid/ciw530
ISSN:
10584838
Research Areas
Maternal And Child Health
Study Design
Randomised Control Trial